IRICoR is proud to announce the Dr. Steven Klein, Vice-President Business Development at IRICoR is invited as a speaker at the next Licensing Executives Society workshop to be held September 26, 2017 in Montreal.
The conference will be entitled “Do’s and don’ts in deal negotiation between private industry and universities”. Discussions will focus on the impact a case study: Domain Therapeutics […]
Company is advancing a clinical-stage novel immunotherapy based on technology developed with the support of IRICoR
MONTREAL, QC, September 11, 2017 – SpecificiT Pharma Inc., a privately held Montreal-based biopharmaceutical company focused on developing innovative personalized hematological cancer immunotherapies, is pleased to announce the completion of a seed financing by existing shareholder AmorChem, along with new partners, Sanderling Ventures and Accel-Rx […]
IRICoR announces the appointment of Dr. Martin Godbout as Chairman of its Board of Directors and of Ms. Catherine Bouchard as a new Board Member
Montreal, July 31, 2017— IRICoR (Institute for Research in Immunology and Cancer – Commercialization of Research) proudly announces the appointment of Dr. Martin Godbout, president of Hodran Consultants Inc., as the new Chairman of its Board […]
Montreal, June 1, 2017 — Close to 425 guests joined forces last night at the Caisse de dépôt et placement du Québec’s The Parquet to take part in the 4th edition of the Audacious fundraising event, benefiting the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal. Thanks to their generous contribution, as well as those of our […]
Tel Aviv, May 23, 2017 – As part of his mission to Israel, the Premier of Quebec announced today an agreement between the Hebrew University of Jerusalem and the University of Montreal. It includes the development of new projects in collaboration with the Institute for Research in Immunology and Cancer (IRIC) in the fields of structural biology, molecular pharmacology and drug […]
Hot topics in Immuno-Oncology and Genetic Therapies
IRICoR, the Institute for Research in Immunology and Cancer – Commercialization of Research of Université de Montréal, in association with Defined Health, a leading business development strategy consulting firm, are pleased to invite you to its Business Seminar.
Date and time: Wednesday, June 14, 2017 at noon
Where : Room S1-151, Jean Coutu Pavilion
Registration is required. […]
For the annual edition of the Canadian Society for Pharmaceutical Sciences (CSPS) and the Canadian Chapter of the Controlled Release Society (CC-CRS) conferences, Mrs. Nadine Beauger, Chief Executive Officer at the Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR), was invited to present her organization’s model as Université de Montréal’s key drug discovery and project maturation […]
The Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR), Université de Montréal’s drug discovery and project maturation unit based at the Institute for Research in Immunology and Cancer (IRIC), whose mandate is to accelerate the discovery, development and commercialization of novel therapies in cancer and related fields, has entered into a strategic collaboration with AstraZeneca, a […]
The Institute for Research in Immunology and Cancer — Commercialization of Research (IRICoR) is pleased to announce that its clinical-stage spin-off company, ExCellThera, won the $20,000 first prize in the Pharma & Biotech category at the HealthKick Challenge, which took place in Toronto, Ontario, on April 5th.
ExCellThera, the result of IRICoR’s collaboration with the Centre for Commercialization of […]
Novel Approach to Identifying TSAs based on a unique mass spectrometry approach discovered at IRIC combined with expertise in genomic sequencing and clinical validation from C3i
Montreal, April 4, 2017 — The Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR) and the Centre for Commercialization of Cancer Immunotherapy (C3i) are pleased to announce a major collaboration to […]
